Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

XLO

Xilio Therapeutics Inc

Nov 05 • 04:00PM ET

0.8154

+0.0136 1.70 %

Healthcare • Biotechnology • USA • NASD

Peers: BNTX VRTX MRNA AZN ALXO NBIX ARVN IMVT ADPT FOLD

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.77	Insider Own	56.79%	Shs Outstand	51.83M	Perf Week	0.67%
Market Cap	42.26M	Forward P/E	-	EPS next Y	-0.32	Insider Trans	0.36%	Shs Float	22.39M	Perf Month	-0.84%
Enterprise Value	-71.72M	PEG	-	EPS next Q	-0.03	Inst Own	18.99%	Short Float	23.46%	Perf Quarter	24.41%
Income	-56.22M	P/S	2.82	EPS this Y	58.72%	Inst Trans	4.85%	Short Ratio	7.70	Perf Half Y	22.34%
Sales	15.00M	P/B	5.98	EPS next Y	30.00%	ROA	-50.27%	Short Interest	5.25M	Perf YTD	-14.62%
Book/sh	0.14	P/C	0.35	EPS next 5Y	15.19%	ROE	-277.74%	52W High	1.70 -52.04%	Perf Year	-38.23%
Cash/sh	2.35	P/FCF	-	EPS past 3/5Y	26.76% -11.55%	ROIC	-420.48%	52W Low	0.62 32.59%	Perf 3Y	-65.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	88.52%	Volatility	9.18% 7.47%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-4.78	EPS Y/Y TTM	63.68%	Oper. Margin	-377.63%	ATR (14)	0.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.32	Sales Y/Y TTM	536.44%	Profit Margin	-374.79%	RSI (14)	54.30	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.32	EPS Q/Q	31.85%	SMA20	3.14%	Beta	-0.06	Target Price	2.00
Payout	-	Debt/Eq	1.07	Sales Q/Q	242.98%	SMA50	5.34%	Rel Volume	1.63	Prev Close	0.80
Employees	64	LT Debt/Eq	0.89	Earnings	Aug 14 BMO	SMA200	5.94%	Avg Volume	681.83K	Price	0.82
IPO	Oct 22, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-103.05% -1.46%	Trades		Volume	1,151,973	Change	1.70%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-25	Initiated	Leerink Partners	Outperform	$2
Dec-21-22	Initiated	Chardan Capital Markets	Buy	$7
Jan-10-22	Initiated	H.C. Wainwright	Buy	$36
Nov-16-21	Initiated	Raymond James	Outperform	$31
Nov-16-21	Initiated	Morgan Stanley	Overweight	$32
Nov-16-21	Initiated	Guggenheim	Buy	$40
Nov-16-21	Initiated	Cowen	Outperform

Nov-03-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.68% -5.66%
Oct-30-25 09:01AM	Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting (GlobeNewswire)
Oct-03-25 09:00AM	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting (GlobeNewswire)
Oct-02-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-25 07:30AM	Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead (GlobeNewswire) +7.81%
08:35AM	Loading…
Aug-14-25 08:35AM	Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
Aug-04-25 08:03AM	Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors (GlobeNewswire)
Aug-01-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-28-25 05:05PM	Bristol Myers Squibb and Bain Capital Form New Immunology Company (The Wall Street Journal)
Jul-02-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-10-25 04:30PM	Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors (GlobeNewswire)
Jun-05-25 06:38PM	Xilio Therapeutics Announces Closing of $50.0 Million Public Offering (GlobeNewswire)
Jun-03-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:46AM	Loading…
Jun-02-25 08:46AM	Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering (GlobeNewswire) -34.57%
06:11AM	Xilio Therapeutics Announces Proposed Public Offering (GlobeNewswire)
May-31-25 08:00AM	Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer (GlobeNewswire)
May-08-25 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results (GlobeNewswire) +8.03%
May-02-25 04:30PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-23-25 04:30PM	Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting (GlobeNewswire) +5.55%
Apr-04-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-25 08:45AM	Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.20%
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 04:30PM	Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -5.13%
Feb-13-25 04:17AM	AbbVie and Xilio to collaborate on antibody-based immunotherapies (Pharmaceutical Technology) -12.84%
Feb-12-25 10:44AM	Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? (Benzinga) +125.27%
07:35AM	Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs (GlobeNewswire)
07:33AM	AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies (GlobeNewswire)
Feb-03-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.30%
09:00AM	Loading…
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire) -29.91%
Jan-21-25 05:05PM	Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer (GlobeNewswire) +11.40%
Jan-17-25 04:30PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-10-25 05:00PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-24 07:30AM	Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI (GlobeNewswire) +8.25%
Dec-16-24 07:30AM	Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer (GlobeNewswire)
Dec-09-24 09:55AM	After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright (Zacks)
Dec-03-24 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 09:15AM	Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors (GlobeNewswire) -19.38%
09:05AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:01AM	Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire) +38.38%
Oct-04-24 09:05AM	Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire) +7.51%
Oct-02-24 04:15PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-24 04:01PM	Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire) -10.98%
Aug-08-24 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-13-24 04:05PM	Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors (GlobeNewswire)
May-29-24 06:05AM	Gilead and Cartography enter deal to develop cancer therapies (Pharmaceutical Technology)
May-14-24 01:54PM	XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-16-24 09:14AM	Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why (Zacks)
Apr-01-24 10:53PM	XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +41.67%
04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-28-24 11:10AM	Why Is Xilio Therapeutics (XLO) Stock up 168% Today? (InvestorPlace) +69.01%
07:05AM	Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing (GlobeNewswire)
07:00AM	Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program (GlobeNewswire)
06:45AM	Gilead bets on Xilio cancer drug as biotech restructures (BioPharma Dive)
Feb-28-24 04:01PM	Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +5.60% +7.42%
Jan-31-24 04:01PM	Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:30AM	Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies (GlobeNewswire)
Dec-07-23 07:30AM	Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data (GlobeNewswire)
Nov-09-23 04:01PM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire) -13.04% -10.63%
Nov-03-23 12:00PM	Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors (GlobeNewswire)
Oct-31-23 09:15AM	Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting (GlobeNewswire)
Sep-27-23 05:02PM	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-05-23 08:30AM	Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer (GlobeNewswire)
07:30AM	Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-18-23 04:27AM	Q2 2023 Xilio Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:05PM	Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer (GlobeNewswire)
May-25-23 05:01PM	Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors (GlobeNewswire)
May-09-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-03-23 04:05PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.09%
Mar-02-23 04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -7.37%
Feb-27-23 07:30AM	Xilio Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.72%
Feb-16-23 07:30AM	Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-02-23 07:30AM	Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-26-23 05:30AM	Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most (Simply Wall St.)
Jan-25-23 09:45AM	These 2 Strong Buy Penny Stocks Are on Track for Massive Gains, Say Analysts (TipRanks) +36.92%
Nov-23-22 07:30AM	Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12 (GlobeNewswire) +7.94%
Nov-09-22 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 07:30AM	Xilio Therapeutics to Present at Cowen 6th Annual IO Next Summit (GlobeNewswire)
Sep-22-22 04:05PM	Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference (GlobeNewswire)
Sep-15-22 04:05PM	Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors (GlobeNewswire) +15.38%
Sep-06-22 04:05PM	Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +8.21%
Aug-11-22 09:41AM	Is Xilio Therapeutics (NASDAQ:XLO) In A Good Position To Invest In Growth? (Simply Wall St.)
Aug-09-22 07:30AM	Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results (GlobeNewswire) -26.22%
Jun-16-22 07:30AM	Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President (GlobeNewswire)
May-18-22 07:30AM	Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -9.56%
May-17-22 07:30AM	Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer (GlobeNewswire) -5.18%
May-12-22 07:30AM	Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results (GlobeNewswire)
Apr-07-22 06:30AM	Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-01-22 06:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -7.56%
Feb-28-22 06:30AM	Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference (GlobeNewswire) -10.42%
Feb-07-22 05:38PM	RiverVest Venture Management LLC Buys Xilio Therapeutics Inc (GuruFocus.com)
Feb-03-22 06:30AM	Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day (GlobeNewswire)
Jan-25-22 10:27AM	Are Institutions Heavily Invested In Xilio Therapeutics, Inc.'s (NASDAQ:XLO) Shares? (Simply Wall St.)
Jan-20-22 07:30AM	Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors (GlobeNewswire) +9.79%
Jan-06-22 07:30AM	Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors (GlobeNewswire)
Dec-02-21 07:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results (GlobeNewswire) -12.46%
Nov-12-21 07:00AM	Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting (GlobeNewswire) -6.69%

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shannon James Samuel	Director	Jun 16 '25	Buy	0.69	45,000	30,870	45,000	Jun 18 04:57 PM
Shannon James Samuel	Director	Jun 17 '25	Buy	0.69	25,000	17,215	70,000	Jun 18 04:57 PM
Russo Rene	PRESIDENT AND CEO	Jun 16 '25	Buy	0.68	36,289	24,680	281,172	Jun 18 04:56 PM
Frankenfield Christopher James	Chief Financial Officer	Jan 02 '25	Sale	0.98	6,954	6,841	12,421	Jan 03 04:15 PM
Brennan Kevin M.	SVP, FINANCE AND ACCOUNTING	Jan 02 '25	Sale	0.98	1,803	1,774	3,197	Jan 03 04:15 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 18 '24	Buy	1.04	1,759,978	1,830,377	9,105,451	Dec 19 04:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XLO

Xilio Therapeutics Inc

Upgrade your FINVIZ experience